All In Biotech

Drug Trial Radar · NCT06578507

Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease

Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children With Sickle Cell Disease: a Single-group, Non-randomised, Open-label Study (KID-BID)

Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Jan 21, 2025

Primary completion

Feb 2028

Study completion Feb 2028

Sponsor

Lead sponsor
TheraviaIndustry
Sponsor type
Industry
First posted
Aug 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 9 months, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this interventional, phase II, national, multicentric, non-randomised, open-label study is to evaluate the pharmacokinetics (PK), efficacy and safety of Hydroxycarbamide Paediatric dispersible tablets with a twice daily dosing regimen in children with Sickle Celle Disease between 9 months to 11 years of age. Participants will: * Take Hydroxycarbamide twice a day every day for 12 months * Visit the clinic at screening, baseline, 1, 3, 6, 9 and 12 months

Conditions

  • Sickle Cell Disease

Interventions

  • HydroxycarbamidDrug

    Hydroxycarbamide Paediatric dispersible tablets will be provided in the form of film-coated dispersible tablets containing 50 mg of hydroxycarbamide. The IMP will be administered as half-strength twice daily, based on the body weight of the patient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the PK exposure for Hydroxycarbamide Paediatric dispersible tablets administered BID through area under the curve (AUC)Time frame: 1, 3, 6, 9 and 12 months after treatment initiation
  2. Evaluate the PK exposure for Hydroxycarbamide Paediatric dispersible tablets administered BID through time to obtain the maximum concentration (Tmax)Time frame: 1, 3, 6, 9 and 12 months after treatment initiation
  3. Evaluate the PK exposure for Hydroxycarbamide Paediatric dispersible tablets administered BID through maximum plasma concentration (Cmax)Time frame: 1, 3, 6, 9 and 12 months after treatment initiation

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • Centre Hospitalier Intercommunal Créteil

    Créteil, France · Recruiting

  • GHEF- Site de Marne-la-Vallée

    Jossigny, France · Recruiting

  • Hôpital Bicêtre

    Le Kremlin-Bicêtre, France · Recruiting

  • Institut d'Hématologie et d'oncologie pédiatrique - IHOPe

    Lyon, France · Suspended

  • Hôpital Necker-Enfants malades

    Paris, France · Recruiting

  • CH Saint-Denis

    Saint-Denis, France · Recruiting

  • Centre hospitalier de Cayenne

    Cayenne, French Guiana · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.